Meeting
2022 ASCO Genitourinary Cancers Symposium
Prognostic value of HER2 expression levels for upper tract urothelial carcinoma.
Authors
Siming Li
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital & Institute, Collaborative Innovation Center of Cancer Medicine, Beijing, China
Siming Li , Xiaowen Wu , Xieqiao Yan , Li Zhou , Huayan Xu , Juan Li , Yiqiang Liu , Bixia Tang , Zhihong Chi , Lu Si , Jun Guo , Xinan Sheng
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 557)
DOI
10.1200/JCO.2022.40.6_suppl.557
Abstract #
557
Poster Bd #
K1
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Evaluation of tumor MET protein expression, MET gene amplification, and HER2 expression in Chinese patients with advanced gastric or gastroesophageal junction (G/GEJ) cancer.
First Author: Rui-hua Xu
Poster
2013 Gastrointestinal Cancers Symposium
Differential HER2 expression in resected gastric cancer: Is there prognostic value?
First Author: Sarah Fisher
Poster
2024 ASCO Breakthrough
Differences in the expression heterogeneity of ADC-related markers between primary tumors and metastatic lymph nodes in advanced urothelial cancers.
First Author: Xingliang Tan
Poster
2022 ASCO Annual Meeting
CDK4/6 inhibitors outcomes in patients with advanced breast cancer based on HER2-low expression.
First Author: Laura Sabina Lapuchesky